Background regimen

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Acquired Immune Deficiency Syndrome (AIDS)HIV InfectionHIV Infections

Phase 2

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

TerminatedNCT01923311

Gilead SciencesAcquired Immune Deficiency Syndrome (AIDS), HIV Infections

Start: 2013-08-26End: 2017-11-03Updated: 2018-08-09

Phase 3

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

CompletedNCT00708162

Gilead SciencesHIV Infection

Start: 2008-07-31End: 2015-04-30Updated: 2016-05-30

Related Papers

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

2011-10-18126 citations